The PBS subsidises aflibercept and ranibizumab for patients with branched retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), with macular oedema.
Aflibercept and ranibizumab can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with retinal vein occlusion with macular oedema.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept and ranibizumab.
Patients must be treated by an ophthalmologist to be eligible for PBS subsidised treatment with these medications.
Make all initial applications for authority approval to prescribe aflibercept and ranibizumab for the treatment of retinal vein occlusion with macular oedema in writing and:
- upload through Health Professional Online Services, or
- post to the PBS Complex Drugs Programs address
All applications must include:
- a completed authority prescription form
- a completed Retinal Vein Occlusion Initial PBS authority application form
- any relevant attachments
You can make an application for continuing treatment by calling the PBS Complex Drugs Programs enquiry line.
Emergency treatments only
To avoid a delay in starting treatment, you can fax the completed authority application form, authority prescription form and any relevant attachments to the PBS Complex Drugs Programs team, who will contact the prescriber by phone. You are no longer required to send the original authority prescriptions form, authority application form and any relevant attachments.
For more information call the PBS Complex Drugs Programs enquiry line.